考比替尼

考比替尼（CAS 934660-93-2）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的记载用途

Cobimetinib is indicated in combination with [vemurafenib] for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. As a single agent, cobimetinib is also indicated for the treatment of adult patients with histiocytic neoplasms.Cobimetinib is a tyrosine kinase receptor inhibitor that is used in combination with vemurafenib as therapy for selected forms of advanced malignant melanoma. The combination of cobimetinib and vemurafenib is commonly associated with serum enzyme elevations during therapy and to rare instances of clinically apparent acute liver injury.

同义词与商品名

Cobimetinib; 934660-93-2; GDC-0973; XL518; Cotellic; GDC 0973; Xl-518; RG7420; XL 518; RG 7420; ER29L26N1X; CHEBI:90851; DTXSID60239435; 1-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzoyl}-3-[(2S)-piperidin-2-yl]azetidin-3-ol; cobimetinibum; 1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoyl)-3-((2S)-piperidin-2-yl)azetidin-3-ol

公开数据库对它的描述

Cobimetinib · CAS 934660-93-2 · C21H21F3IN3O2. UNII ER29L26N1X.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。